TERT promoter mutations in primary and secondary glioblastomas
Identifieur interne : 001476 ( Main/Exploration ); précédent : 001475; suivant : 001477TERT promoter mutations in primary and secondary glioblastomas
Auteurs : Naosuke Nonoguchi [France, Japon] ; Takashi Ohta [France] ; Ji-Eun Oh [France] ; Young-Ho Kim [France, Corée du Sud] ; Paul Kleihues [Suisse] ; Hiroko Ohgaki [France]Source :
- Acta Neuropathologica [ 0001-6322 ] ; 2013-12-01.
English descriptors
Abstract
Abstract: Telomerase reverse transcriptase (TERT) is up-regulated in a variety of human neoplasms. Mutations in the core promoter region of the TERT gene, which increases promoter activity, have been reported in melanomas and a variety of human neoplasms, including gliomas. In the present study, we screened for TERT promoter mutations by direct DNA sequencing in a population-based collection of 358 glioblastomas. TERT promoter mutations (C228T, C250T) were detected in 55 % glioblastomas analysed. Of these, 73 % had a C228T mutation, and 27 % had a C250T mutation; only one glioblastoma had both C228T and C250T mutations. TERT promoter mutations were significantly more frequent in primary (IDH1 wild-type) glioblastomas (187/322; 58 %) than in secondary (IDH1 mutated) glioblastomas (10/36, 28 %; P = 0.0056). They showed significant inverse correlations with IDH1 mutations (P = 0.0056) and TP53 mutations (P = 0.043), and a significant positive correlation with EGFR amplification (P = 0.048). Glioblastoma patients with TERT mutations showed a shorter survival than those without TERT mutations in univariate analysis (median, 9.3 vs. 10.5 months; P = 0.015) and multivariate analysis after adjusting for age and gender (HR 1.38, 95 % CI 1.01–1.88, P = 0.041). However, TERT mutations had no significant impact on patients’ survival in multivariate analysis after further adjusting for other genetic alterations, or when primary and secondary glioblastomas were separately analysed. These results suggest that the prognostic value of TERT mutations for poor survival is largely due to their inverse correlation with IDH1 mutations, which are a significant prognostic marker of better survival in patients with secondary glioblastomas.
Url:
DOI: 10.1007/s00401-013-1163-0
Affiliations:
- Corée du Sud, France, Japon, Suisse
- Auvergne-Rhône-Alpes, Canton de Zurich, Rhône-Alpes
- Lyon, Zurich
- Université de Zurich
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000136
- to stream Istex, to step Curation: 000136
- to stream Istex, to step Checkpoint: 000102
- to stream Main, to step Merge: 001488
- to stream Main, to step Curation: 001476
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">TERT promoter mutations in primary and secondary glioblastomas</title><author><name sortKey="Nonoguchi, Naosuke" sort="Nonoguchi, Naosuke" uniqKey="Nonoguchi N" first="Naosuke" last="Nonoguchi">Naosuke Nonoguchi</name></author><author><name sortKey="Ohta, Takashi" sort="Ohta, Takashi" uniqKey="Ohta T" first="Takashi" last="Ohta">Takashi Ohta</name></author><author><name sortKey="Oh, Ji Eun" sort="Oh, Ji Eun" uniqKey="Oh J" first="Ji-Eun" last="Oh">Ji-Eun Oh</name></author><author><name sortKey="Kim, Young Ho" sort="Kim, Young Ho" uniqKey="Kim Y" first="Young-Ho" last="Kim">Young-Ho Kim</name></author><author><name sortKey="Kleihues, Paul" sort="Kleihues, Paul" uniqKey="Kleihues P" first="Paul" last="Kleihues">Paul Kleihues</name></author><author><name sortKey="Ohgaki, Hiroko" sort="Ohgaki, Hiroko" uniqKey="Ohgaki H" first="Hiroko" last="Ohgaki">Hiroko Ohgaki</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:065229B016D6423B8DC7E546957018A5C227DB86</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1007/s00401-013-1163-0</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-0CSCXPFM-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000136</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000136</idno><idno type="wicri:Area/Istex/Curation">000136</idno><idno type="wicri:Area/Istex/Checkpoint">000102</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000102</idno><idno type="wicri:doubleKey">0001-6322:2013:Nonoguchi N:tert:promoter:mutations</idno><idno type="wicri:Area/Main/Merge">001488</idno><idno type="wicri:Area/Main/Curation">001476</idno><idno type="wicri:Area/Main/Exploration">001476</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">TERT promoter mutations in primary and secondary glioblastomas</title><author><name sortKey="Nonoguchi, Naosuke" sort="Nonoguchi, Naosuke" uniqKey="Nonoguchi N" first="Naosuke" last="Nonoguchi">Naosuke Nonoguchi</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Section of Molecular Pathology, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurosurgery, Osaka Medical College, Takatsuki</wicri:regionArea><wicri:noRegion>Takatsuki</wicri:noRegion></affiliation></author><author><name sortKey="Ohta, Takashi" sort="Ohta, Takashi" uniqKey="Ohta T" first="Takashi" last="Ohta">Takashi Ohta</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Section of Molecular Pathology, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Oh, Ji Eun" sort="Oh, Ji Eun" uniqKey="Oh J" first="Ji-Eun" last="Oh">Ji-Eun Oh</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Section of Molecular Pathology, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Kim, Young Ho" sort="Kim, Young Ho" uniqKey="Kim Y" first="Young-Ho" last="Kim">Young-Ho Kim</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Section of Molecular Pathology, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Translational Epidemiology Research Branch, National Cancer Center, Goyang</wicri:regionArea><wicri:noRegion>Goyang</wicri:noRegion></affiliation></author><author><name sortKey="Kleihues, Paul" sort="Kleihues, Paul" uniqKey="Kleihues P" first="Paul" last="Kleihues">Paul Kleihues</name><affiliation wicri:level="4"><country xml:lang="fr">Suisse</country><wicri:regionArea>Medical Faculty, University of Zurich, 8091, Zurich</wicri:regionArea><orgName type="university">Université de Zurich</orgName><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region></placeName></affiliation></author><author><name sortKey="Ohgaki, Hiroko" sort="Ohgaki, Hiroko" uniqKey="Ohgaki H" first="Hiroko" last="Ohgaki">Hiroko Ohgaki</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Section of Molecular Pathology, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neuropathologica</title><title level="j" type="sub">Pathology and Mechanisms of Neurological Disease</title><title level="j" type="abbrev">Acta Neuropathol</title><idno type="ISSN">0001-6322</idno><idno type="eISSN">1432-0533</idno><imprint><publisher>Springer Berlin Heidelberg</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2013-12-01">2013-12-01</date><biblScope unit="volume">126</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="931">931</biblScope><biblScope unit="page" to="937">937</biblScope></imprint><idno type="ISSN">0001-6322</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6322</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>IDH1 mutations</term><term>Primary glioblastomas</term><term>Secondary glioblastomas</term><term>TERT promoter mutations</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Telomerase reverse transcriptase (TERT) is up-regulated in a variety of human neoplasms. Mutations in the core promoter region of the TERT gene, which increases promoter activity, have been reported in melanomas and a variety of human neoplasms, including gliomas. In the present study, we screened for TERT promoter mutations by direct DNA sequencing in a population-based collection of 358 glioblastomas. TERT promoter mutations (C228T, C250T) were detected in 55 % glioblastomas analysed. Of these, 73 % had a C228T mutation, and 27 % had a C250T mutation; only one glioblastoma had both C228T and C250T mutations. TERT promoter mutations were significantly more frequent in primary (IDH1 wild-type) glioblastomas (187/322; 58 %) than in secondary (IDH1 mutated) glioblastomas (10/36, 28 %; P = 0.0056). They showed significant inverse correlations with IDH1 mutations (P = 0.0056) and TP53 mutations (P = 0.043), and a significant positive correlation with EGFR amplification (P = 0.048). Glioblastoma patients with TERT mutations showed a shorter survival than those without TERT mutations in univariate analysis (median, 9.3 vs. 10.5 months; P = 0.015) and multivariate analysis after adjusting for age and gender (HR 1.38, 95 % CI 1.01–1.88, P = 0.041). However, TERT mutations had no significant impact on patients’ survival in multivariate analysis after further adjusting for other genetic alterations, or when primary and secondary glioblastomas were separately analysed. These results suggest that the prognostic value of TERT mutations for poor survival is largely due to their inverse correlation with IDH1 mutations, which are a significant prognostic marker of better survival in patients with secondary glioblastomas.</div></front></TEI><affiliations><list><country><li>Corée du Sud</li><li>France</li><li>Japon</li><li>Suisse</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Canton de Zurich</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li><li>Zurich</li></settlement><orgName><li>Université de Zurich</li></orgName></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Nonoguchi, Naosuke" sort="Nonoguchi, Naosuke" uniqKey="Nonoguchi N" first="Naosuke" last="Nonoguchi">Naosuke Nonoguchi</name></region><name sortKey="Kim, Young Ho" sort="Kim, Young Ho" uniqKey="Kim Y" first="Young-Ho" last="Kim">Young-Ho Kim</name><name sortKey="Oh, Ji Eun" sort="Oh, Ji Eun" uniqKey="Oh J" first="Ji-Eun" last="Oh">Ji-Eun Oh</name><name sortKey="Ohgaki, Hiroko" sort="Ohgaki, Hiroko" uniqKey="Ohgaki H" first="Hiroko" last="Ohgaki">Hiroko Ohgaki</name><name sortKey="Ohgaki, Hiroko" sort="Ohgaki, Hiroko" uniqKey="Ohgaki H" first="Hiroko" last="Ohgaki">Hiroko Ohgaki</name><name sortKey="Ohta, Takashi" sort="Ohta, Takashi" uniqKey="Ohta T" first="Takashi" last="Ohta">Takashi Ohta</name></country><country name="Japon"><noRegion><name sortKey="Nonoguchi, Naosuke" sort="Nonoguchi, Naosuke" uniqKey="Nonoguchi N" first="Naosuke" last="Nonoguchi">Naosuke Nonoguchi</name></noRegion></country><country name="Corée du Sud"><noRegion><name sortKey="Kim, Young Ho" sort="Kim, Young Ho" uniqKey="Kim Y" first="Young-Ho" last="Kim">Young-Ho Kim</name></noRegion></country><country name="Suisse"><region name="Canton de Zurich"><name sortKey="Kleihues, Paul" sort="Kleihues, Paul" uniqKey="Kleihues P" first="Paul" last="Kleihues">Paul Kleihues</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001476 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001476 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:065229B016D6423B8DC7E546957018A5C227DB86
|texte= TERT promoter mutations in primary and secondary glioblastomas
}}
| This area was generated with Dilib version V0.6.33. |  |